In the meanwhile, recently, for the goal of distinguishing clear cell RCC from other renal tumors, including benign renal mass, Zirconium-89-girentuximab PET/CT, which targets CAIX membrane protein has been developed [31]. Here, CA9 is linked to neoplasm.